This one is a big stretch.
Latest News:
- An Attack Ad That Claims Michigan Sen. Gary Peters Supports ‘Medicare For All’ Doesn’t Hold Up
- California Reopens The Single-Payer Debate
- Conceived Through ‘Fertility Fraud,’ She Now Needs Fertility Treatment
- Medi-Cal Benefits Eliminated A Decade Ago, Such As Foot Care And Eyeglasses, Are Back
- Call For FDA To Withdraw Preterm Birth Drug Divides Doctors and Insurers
- Bloomberg On Health Care: Translating His Mayoral Record To The National Stage
- Despite New Doubts, ‘Hotspotting’ Help For Heavy Health Care Users Marches On
- Something Far Deadlier Than The Wuhan Virus Lurks Near You
What do contract employees, students taking a break from school to go back to work, employees working for low wages and those between jobs have in common? Known as “the gap population,” this group faces a unique difficulty when securing affordable, long-term health insurance.
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.
Budget cuts in 2009, sparked by the Great Recession, eliminated many needed health care services, like regular foot care for people with diabetes to minimize the risk of amputation. The restored benefits also include eyeglasses, speech therapy and hearing exams.
There is a virus that has already sickened at least 13 million Americans this winter, hospitalizing 120,000 and killing 6,600 people. You may even know of it.
Years ago, doctors sometimes lied about whose sperm they used for artificial inseminations. Could it happen now? Some argue regulation is weak in the multibillion-dollar fertility treatment industry.
A high-profile commission created by Gov. Gavin Newsom will convene for the first time Monday to discuss how to get every Californian covered. But don’t expect the state to adopt a single-payer system anytime soon.
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.
A high-profile effort in Camden, New Jersey, to reduce health spending by identifying high-cost patients and giving them more coordinated and preventive medical care has been copied around the country. Many of those groups are pushing forward with the efforts, despite a recent critical study of the Camden initiative.
Years ago, doctors sometimes lied about whose sperm they used for artificial inseminations. Could it happen now? Some argue regulation is weak in the multibillion-dollar fertility treatment industry.
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.
A high-profile effort in Camden, New Jersey, to reduce health spending by identifying high-cost patients and giving them more coordinated and preventive medical care has been copied around the country. Many of those groups are pushing forward with the efforts, despite a recent critical study of the Camden initiative.
The web-based standard FHIR — pronounced “fire” — could hasten the day when we can view our full medical histories on a smartphone screen. Tech giants are hungry for a piece of the pie, but obstacles remain.
A number of radiology organizations are trying to end the decades-old practice of shielding patients from radiation with lead aprons. They say it provides no benefit and might even inadvertently expose people to higher radiation levels. But the policy about-face is moving slowly.
Democratic presidential candidates also returned to now-familiar themes in debating the differences between “Medicare for All” and more incremental reforms.
A high-profile commission created by Gov. Gavin Newsom will convene for the first time Monday to discuss how to get every Californian covered. But don’t expect the state to adopt a single-payer system anytime soon.
This one is a big stretch.
Former New York City Mayor Michael Bloomberg uses health care as a key message in his Democratic presidential primary run.
The Supreme Court said it won’t hear an expedited case that threatens to overturn the Affordable Care Act. That means the future of the ACA will continue to be a top political issue through the November election. Meanwhile, a major doctors’ group endorses “Medicare for All.” Sort of. And both sides in the abortion debate mark the 47th anniversary of the Supreme Court’s landmark Roe v. Wade ruling. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.